

Cases from the Community: Investigators Discuss Emerging Research and Actual Patients with Colorectal Cancer (Faculty Presentations)

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- 1. The Phase III KEYNOTE-177 trial comparing pembrolizumab to standard of care chemotherapy as first-line therapy for patients with microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (mCRC) demonstrated which of the following progression-free survival (PFS) outcomes?**
 - a. No significant improvement in PFS between treatment arms
 - b. No significant improvement in PFS2 (PFS on next line of therapy or death from any cause) between treatment arms
 - c. A significant improvement in PFS only in favor of pembrolizumab
 - d. A significant improvement in both PFS and PFS2 in favor of pembrolizumab
- 2. On the basis of the results of the Phase III BEACON CRC trial, which of the following combinations recently received FDA approval as treatment for previously treated mCRC harboring a BRAF V600E mutation?**
 - a. Encorafenib/cetuximab/binimetinib
 - b. Encorafenib/cetuximab
 - c. Encorafenib/binimetinib/FOLFIRI
 - d. Encorafenib/cetuximab/chemotherapy
- 3. Which of the following adverse events is associated with the antibody-drug conjugate trastuzumab deruxtecan (T-DXd)?**
 - a. QT interval prolongation
 - b. Pneumonitis/interstitial lung disease
 - c. Dysgeusia
- 4. At the 2021 Gastrointestinal Cancers Symposium, Van Cutsem and colleagues presented the final overall survival analysis of the results from the Phase II TASCO1 trial of bevacizumab in combination with either TAS-102 or capecitabine for patients with unresectable mCRC. In which setting was the trial studied?**
 - a. First line for patients who are ineligible for intensive therapy
 - b. Second line after disease progression on regorafenib
 - c. Third line or later
- 5. Which of the following best describes the mechanism of action of napabucasin, an investigational agent being studied in the ongoing Phase III CanStem303C trial for patients with previously treated mCRC?**
 - a. Cancer stemness inhibitor
 - b. HER2 inhibitor
 - c. BRAF inhibitor